The Trump administration took its biggest step yet toward letting pharmacies legally make BPC-157. The injectable peptide sits on the FDA's own list of substances too risky to compound. On Thursday, October 15, the Department of Health and Human Services sent the White House budget office an "interim access policy for compounding using certain peptides." STAT reported ↗ the filing, which Reuters and the Associated Press also confirmed. It is the first official trace of a plan health secretary Robert F. Kennedy Jr. has pushed for months.
BPC-157 is sold online to heal injuries and build muscle, and nicknamed Wolverine. It is one of the peptides the plan would cover, according to two people the Associated Press cited. The FDA has never approved it as safe or effective. It sits in the compounding category the agency labels too risky, alongside more than a dozen other injectable peptides.
The filing itself discloses almost nothing. The public document at the Office of Management and Budget names no peptides and sets no rules. What it signals is a mechanism, and the mechanism is the story.
That mechanism is enforcement discretion. Federal law lets state-licensed pharmacies compound many drugs under Section 503A of the Food, Drug, and Cosmetic Act, but these peptides are not eligible. The FDA would not formally add the peptides to the approved compounding list. Doing that takes rulemaking and rounds of public comment that run for years. Instead, the agency would simply tell pharmacies it will not act against them for making the drugs. The peptides stay unapproved. The agency just agrees to look the other way. Enforcement discretion is not approval, and it does not generate the clinical evidence approval requires.
That evidence gap has not moved. In July, the FDA's own staff scientists told an advisory panel that none of seven peptides under review had been studied enough to establish whether they are safe and effective. The outside panel, which included doctors and consultants who work in the peptide field, voted to drop the restrictions anyway ↗. Thursday's filing turns that recommendation into an executive-branch plan headed for approval.
The throughline is Kennedy. Before taking over HHS, he said he would end what he called the FDA's war on peptides. As secretary, he directed the agency to reconsider them, and he helped pick the panel that reviewed them. Conditions still reportedly under discussion include patient disclosures, serious adverse-event reporting, and data collection on how the peptides get used. None are final.
On peptidemodel, BPC-157 ↗ is tagged to tissue repair ↗. It reached Phase 2 trials for inflammatory bowel disease, then stalled. The strongest human data behind it remains a twelve-patient case series. That is almost nothing by the standard any approved drug has to clear. A policy that lets pharmacies sell it changes who the FDA will prosecute. It does not change what anyone actually knows about whether the drug works.